help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Deyo, S. N.
Right arrow Articles by Fang, V. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Deyo, S. N.
Right arrow Articles by Fang, V. S.

Endocrinology, Vol 106, 1469-1474, Copyright © 1980 by Endocrine Society

ARTICLES

Development of tolerance to the prolactin-releasing action of morphine and its modulation by hypothalamic dopamine

SN Deyo, RM Swift, RJ Miller and VS Fang

Exogenous and endogenous opioids are known to stimulate PRL release by the anterior pituitary. Morphine and the opioid peptides [D-Ala2, D- Leu5]enkephalin and beta-endorphin have also been shown to decrease dopamine (DA) release by nerve terminals in the median eminence. The present study examined the ability of morphine sulfate (MS) to decrease DA turnover in the median eminence and increase plasma PRL concentrations in rats made tolerant to opioids by chronic treatment with MS. In naive rats, MS (10 mg/kg, sc) caused a mean increase in serum PRL of 79 ng/ml. After treatment with increasing doses of MS for 4 days, the same dose of MS caused an increase of only 18 ng/ml, indicating that tolerance to the PRL-releasing action of MS occurred. In the same animals, tolerance to the ability of MS to slow DA turnover in the median eminence also occurred, as demonstrated by an attenuation of the action of MS to decrease median eminence DA turnover. These results are consistent with the idea that MS and endogenous opioids increase the rate of release of PRL from the adenohypophysis by slowing the release of DA from the median eminence. This, in turn, results in a decrease in the inhibitory tone exerted on pituitary lactotropic cells and, consequently, a greater rate of PRL release.


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
E. J. Wagner, O. K. Ronnekleiv, and M. J. Kelly
Protein Kinase A Maintains Cellular Tolerance to Mu Opioid Receptor Agonists in Hypothalamic Neurosecretory Cells with Chronic Morphine Treatment: Convergence on a Common Pathway with Estrogen in Modulating Mu Opioid Receptor/Effector Coupling
J. Pharmacol. Exp. Ther., June 1, 1998; 285(3): 1266 - 1273.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
E. J. Wagner, G. Zhang, A. H. Lagrange, O. K. Rønnekleiv, and M. J. Kelly
Tolerance to µ-Opioid Receptor Agonists but not Cross-tolerance to gamma -Aminobutyric AcidB Receptor Agonists in Arcuate A12 Dopamine Neurons with Chronic Morphine Treatment
J. Pharmacol. Exp. Ther., February 1, 1997; 280(2): 1057 - 1064.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1980 by The Endocrine Society